Stock AEGIR AEGIRBIO AB
Add to a list
To use this feature you must be a member
Log inSign up

News AegirBio AB

Equities

AEGIR

SE0014401121

Delayed Nasdaq Stockholm
Other stock markets
 08:03:27 2024-04-26 am EDT 		5-day change 1st Jan Change
0.5 SEK +0.91% Intraday chart for AegirBio AB -0.20% -57.26%
Apr. 19 AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract MT
Apr. 09 AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract
MT
AegirBio AB's subsidiary initiates arbitration against Salofa Oy
AQ
AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas
MT
AegirBio Chairman to Resign
MT
AegirBio's chairman has announced his intention to leave the board of directors
AQ
AegirBio AB Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman
CI
AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval
AQ
AegirBio AB Enters into Conditional Agreement on a SEK 45 Million Loan Facility with Atlas Special Opportunities, LLC
CI
AegirBio AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
AegirBio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Aegirbio Expands Oral Health Scientific Advisory Board with Professor Iain L.C. Chapple
AQ
AegirBio AB Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board
CI
Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio's Scientific Advisory Board
AQ
AegirBio AB Appoints Adam S. Cheifetz as Scientific Advisory Board
CI
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 5.00
AQ
AegirBio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
AegirBio Receives Portion of National Institutes of Health Award
MT
AegirBio Shifts Business Focus to Diagnostics Initiative in US
MT
AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program
AQ
Aegirbio AB Receives Phase 1 Award from the National Institutes of Health Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AEGIR Stock
  4. News AegirBio AB